

Joachim Boos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8595615/publications.pdf>

Version: 2024-02-01

49
papers

1,602
citations

331670

21
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

2030
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 49-57.	3.5	26
2	Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 187-198.	1.6	2
3	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 289-300.	1.6	6
4	Adverse Events During Supervised Exercise Interventions in Pediatric Oncologyâ€”A Nationwide Survey. <i>Frontiers in Pediatrics</i> , 2021, 9, 682496.	1.9	17
5	Asparaginase activities during intensified treatment with pegylated <i>E. coli</i> asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 138-145.	1.3	16
6	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 1006-1017.	1.2	72
7	Bioanalysis of doxorubicin aglycone metabolites in human plasma samplesâ€”implications for doxorubicin drug monitoring. <i>Scientific Reports</i> , 2020, 10, 18562.	3.3	9
8	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 435-444.	2.0	11
9	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 37.	2.4	7
10	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019, 104, 1812-1821.	3.5	32
11	Reduced vs. standard dose native <i>E. coli</i> -asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscowâ€”Berlin 2002. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1001-1012.	2.5	10
12	Therapeutic Drug Monitoring of Asparaginase Activityâ€”Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 93-102.	2.0	16
13	Feasibility and effects of a home-based intervention using activity trackers on achievement of individual goals, quality of life and motor performance in patients with paediatric cancer. <i>BMJ Open Sport and Exercise Medicine</i> , 2018, 4, e000322.	2.9	17
14	Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies. <i>Anticancer Research</i> , 2018, 38, 3977-3984.	1.1	3
15	Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase OncasparÂ® in Children with Acute Lymphoblastic Leukemia. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 955-963.	1.6	16
16	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. <i>Clinical Pharmacokinetics</i> , 2017, 56, 215-223.	3.5	5
17	Objectively measured versus self-reported physical activity in children and adolescents with cancer. <i>PLoS ONE</i> , 2017, 12, e0172216.	2.5	21
18	One in Four Questioned Children Faces Problems Regarding Reintegration Into Physical Education at School After Treatment for Pediatric Cancer. <i>Pediatric Blood and Cancer</i> , 2016, 63, 737-739.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Improved 6-year overall survival in AT/RT – results of the registry study Rhabdoid 2007. <i>Cancer Medicine</i> , 2016, 5, 1765-1775.	2.8	73
20	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a European Pediatric Oncology Off-patents Medicines Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1175-1184.	2.3	25
21	Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 495-505.	2.3	12
22	Motor performance in children and adolescents with cancer at the end of acute treatment phase. <i>European Journal of Pediatrics</i> , 2015, 174, 791-799.	2.7	40
23	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1139-1149.	3.5	23
24	Sports in Pediatric Oncology. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 85-90.	0.6	44
25	Experience of barriers and motivations for physical activities and exercise during treatment of pediatric patients with cancer. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1632-1637.	1.5	60
26	Comparison of self-reported physical activity in children and adolescents before and during cancer treatment. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1023-1028.	1.5	62
27	The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. <i>Haematologica</i> , 2014, 99, 1716-1721.	3.5	66
28	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. <i>Blood</i> , 2014, 124, 3027-3029.	1.4	12
29	Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia. <i>Blood</i> , 2014, 124, 2256-2256.	1.4	1
30	The effect of individualized exercise interventions during treatment in pediatric patients with a malignant bone tumor. <i>Supportive Care in Cancer</i> , 2013, 21, 1629-1636.	2.2	35
31	A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2634-2634.	1.4	3
32	Population Pharmacokinetics of Native <i>Escherichia Coli</i> Asparaginase. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 154-165.	0.8	8
33	A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.. <i>Blood</i> , 2012, 120, 2458-2458.	1.4	0
34	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 766-771.	2.0	16
35	The Bone Marrow Niche of Patients with Acute Lymphoblastic Leukemia Produces No Increased Asparagine Levels In Vivo That May Lead to Clinical Asparaginase Resistance. <i>Blood</i> , 2011, 118, 1505-1505.	1.4	0
36	Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. <i>Pediatric Blood and Cancer</i> , 2010, 54, 355-360.	1.5	20

#	ARTICLE	IF	CITATIONS
37	A population pharmacokinetic model for pegylated asparaginase in children. <i>British Journal of Haematology</i> , 2010, 148, 119-125.	2.5	32
38	Level of activity in children undergoing cancer treatment. <i>Pediatric Blood and Cancer</i> , 2009, 53, 438-443.	1.5	116
39	Paediatric and geriatric drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 37-45.	5.0	209
40	Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 883-888.	1.9	24
41	Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. <i>Medical and Pediatric Oncology</i> , 2003, 40, 293-301.	1.0	25
42	Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 133-141.	2.3	45
43	Low dose-high dose: what is the right dose? Pharmacokinetic modeling of etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 303-308.	2.3	4
44	Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum. <i>Analytical Biochemistry</i> , 2002, 309, 117-126.	2.4	76
45	Use of PEG-asparaginase in the treatment of patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 421-422.	2.3	4
46	Pharmacokinetics of native <i>Escherichia coli</i> asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. <i>British Journal of Haematology</i> , 2001, 114, 794-799.	2.5	83
47	Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. <i>British Journal of Haematology</i> , 2000, 110, 379-384.	2.5	113
48	Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. <i>Electrophoresis</i> , 1998, 19, 2939-2943.	2.4	51
49	Letters to the Editor. <i>American Journal of Physiology - Cell Physiology</i> , 1998, 274, C1185-C1185.	4.6	11